Bender Robert & Associates’s UroGen Pharma URGN Stock Holding History

Bender Robert & Associates’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-34,701	Closed	-$624K	–	45
2026 Q1	$624K	Buy	+34,701	New	+$696K	0.15%	30
2025 Q4	–	Sell	-34,701	Closed	-$692K	–	46
2025 Q3	$692K	Hold	34,701	–	–	0.15%	28
2025 Q2	$475K	Buy	+34,701	New	+$333K	0.11%	32
2025 Q1	–	Sell	-34,701	Closed	-$370K	–	48
2024 Q4	$370K	Buy	+34,701	New	+$415K	0.09%	36
2024 Q2	–	Sell	-34,701	Closed	-$521K	–	82
2024 Q1	$521K	Hold	34,701	–	–	0.12%	36
2023 Q4	$521K	Hold	34,701	–	–	0.13%	38
2023 Q3	$486K	Hold	34,701	–	–	0.14%	38
2023 Q2	$359K	Hold	34,701	–	–	0.1%	40
2023 Q1	$321K	Buy	+34,701	New	+$319K	0.1%	45
2022 Q4	–	Sell	-41,131	Closed	-$342K	–	52
2022 Q3	$342K	Hold	41,131	–	–	0.13%	43
2022 Q2	$337K	Buy	+41,131	New	+$282K	0.13%	42
2021 Q2	–	Sell	-31,131	Closed	-$606K	–	54
2021 Q1	$606K	Buy	+31,131	New	+$661K	0.2%	37

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Bender Robert & Associates's URGN Position: Q2 2026 in Review

Bender Robert & Associates sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 34,701 shares — an estimated $624K sold.

Bender Robert & Associates first reported a position in URGN in Q1 2021 and held it in 12 quarters. The position peaked at $692K in Q3 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Bender Robert & Associates reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
Bender Robert & Associates sold 34,701 UroGen Pharma shares in Q2 2026, an estimated $624K.
Bender Robert & Associates first reported a position in UroGen Pharma in Q1 2021 and held it in 12 quarters.
Bender Robert & Associates's UroGen Pharma position peaked at $692K in Q3 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Bender Robert & Associates's 13F filing for Q2 2026, filed 30 Jul 2026.